Suzanne L. Topalian - Concepedia

Author

Suzanne L. Topalian

Also Known As

S L Topalian, S Topalian, S. L. Topalian, S. Topalian, S.L. Topalian, SUZANNE L. TOPALIAN, Suzanne L. Topalian, Suzanne L Topalian, Suzanne L. Topalian, Suzanne Louise Topalian

358

Publications

96.1K

Citations

101

H-Index

120

Concepts

All Affiliations

National Cancer Institute National Institutes of Health Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center Bristol-Myers Squibb (United States)

About

Suzanne L. Topalian is an author at National Cancer Institute specializing in medicine, immunology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	56	102	24.8K
2	Health Sciences	7	7	504
3	Allergy	3	3	550
4	Engineering	2	2	195
5	Natural Sciences	2	2	182

Suzanne L. Topalian

196

Publications

84.8K

Citations

H-Index

Page 1

	Year	Citations
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer, New England Journal of Medicine	2012	12.5K
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer Julie R. Brahmer, Scott S. Tykodi, Laura Q.M. Chow, New England Journal of Medicine	2012	7.9K
Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates Julie R. Brahmer, Charles G. Drake, Ira Wollner, Journal of Clinical Oncology	2010	2.9K
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes Mark E. Dudley, John R. Wunderlich, Paul F. Robbins, Science	2002	2.8K
A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer James Chih‐Hsin Yang, Leah Haworth, Richard M. Sherry, New England Journal of Medicine	2003	2.7K
Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes Richard A. Morgan, Mark E. Dudley, John R. Wunderlich, Science Lymphoid NeoplasiaCell TherapyCancer ImmunosurveillanceMedicineCancer Regression	2006	2.6K
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy Janis M. Taube, Alison Klein, Julie R. Brahmer, Clinical Cancer Research	2014	2.3K
Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma Steven A. Rosenberg, Beverly S. Packard, Paul Aebersold, New England Journal of Medicine ImmunologyMetronomic ChemotherapyImmunotherapyTumor BiologyTumor Immunology	1988	2.3K
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab Suzanne L. Topalian, Mario Sznol, David F. McDermott, Journal of Clinical Oncology	2014	2.2K
Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape Janis M. Taube, Robert A. Anders, Geoffrey D. Young, Science Translational Medicine ImmunologyImmune RegulationImmunoeditingImmunologic MechanismImmunotherapeutics	2012	2.1K

Page 1